Answers are grounded in this paper and cite their sources.
Shows liraglutide improves glycaemic control, body composition, and cardiometabolic markers in adolescents with severe obesity, indicating clinical benefits beyond weight loss.
Childhood obesity is associated with long-term health complications. Liraglutide is approved for use in adolescents for weight loss and has shown beneficial outcomes in clinical trials. Continuous glucose monitoring (CGM) is routinely used in type 1 diabetes mellitus. We aimed to look at the effect of liraglutide treatment on cardiometabolic variables, glycaemic control (as assessed by CGM), body composition, quality-of-life and satiety levels in adolescents with severe obesity.
No takes yet. Share an insight, caveat, or question.
Apperley et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: